Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE

Executive Summary

FDA will offer training next year for reviewers to better understand rare diseases and their associated product applications that could help speed the approval process, although it appears to be optional.

You may also be interested in...



Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes

Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.

Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes

Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.

Rare Disease Improvements Planned Soon, And Up To Five Years From Now

FDA has short- and long-term plans to improve its rare disease program under PDUFA V, and next month the agency will continue its efforts to boost drug development in the sector.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel